Anna Kostera-Pruszczyk
Anna Kostera-Pruszczyk
Verified email at
Cited by
Cited by
Randomized trial of thymectomy in myasthenia gravis
GI Wolfe, HJ Kaminski, IB Aban, G Minisman, HC Kuo, A Marx, P Ströbel, ...
New England Journal of Medicine 375 (6), 511-522, 2016
The TREAT‐NMD DMD Global Database: analysis of more than 7,000 Duchenne muscular dystrophy mutations
CL Bladen, D Salgado, S Monges, ME Foncuberta, K Kekou, K Kosma, ...
Human mutation 36 (4), 395-402, 2015
Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind …
JF Howard Jr, K Utsugisawa, M Benatar, H Murai, RJ Barohn, I Illa, ...
The Lancet Neurology 16 (12), 976-986, 2017
A comprehensive analysis of the epidemiology and clinical characteristics of anti-LRP4 in myasthenia gravis
P Zisimopoulou, P Evangelakou, J Tzartos, K Lazaridis, V Zouvelou, ...
Journal of autoimmunity 52, 139-145, 2014
Long-term effect of thymectomy plus prednisone versus prednisone alone in patients with non-thymomatous myasthenia gravis: 2-year extension of the MGTX randomised trial
GI Wolfe, HJ Kaminski, IB Aban, G Minisman, HC Kuo, A Marx, P Ströbel, ...
The Lancet Neurology 18 (3), 259-268, 2019
Mapping the differences in care for 5,000 spinal muscular atrophy patients, a survey of 24 national registries in North America, Australasia and Europe
CL Bladen, R Thompson, JM Jackson, C Garland, C Wegel, A Ambrosini, ...
Journal of neurology 261 (1), 152-163, 2014
Clinical outcomes in Duchenne muscular dystrophy: a study of 5345 patients from the TREAT-NMD DMD global database
Z Koeks, CL Bladen, D Salgado, E Van Zwet, O Pogoryelova, ...
Journal of neuromuscular diseases 4 (4), 293-306, 2017
A randomized placebo-controlled phase 3 trial of an antisense oligonucleotide, drisapersen, in Duchenne muscular dystrophy
N Goemans, E Mercuri, E Belousova, H Komaki, A Dubrovsky, ...
Neuromuscular Disorders 28 (1), 4-15, 2018
Restrictive cardiomyopathy with atrioventricular conduction block resulting from a desmin mutation
P Pruszczyk, A Kostera-Pruszczyk, A Shatunov, B Goudeau, A Dramiñska, ...
International journal of cardiology 117 (2), 244-253, 2007
Phenotype modifiers of spinal muscular atrophy: the number of SMN2 gene copies, deletion in the NAIP gene and probably gender influence the course of the disease.
M Jedrzejowska, M Milewski, J Zimowski, J Borkowska, ...
Acta Biochimica Polonica 56 (1), 2009
MuSK autoantibodies in myasthenia gravis detected by cell based assay—a multinational study
AI Tsonis, P Zisimopoulou, K Lazaridis, J Tzartos, E Matsigkou, ...
Journal of neuroimmunology 284, 10-17, 2015
Unaffected patients with a homozygous absence of the SMN1 gene
M Jędrzejowska, J Borkowska, J Zimowski, A Kostera-Pruszczyk, ...
European journal of human genetics 16 (8), 930-934, 2008
Amifampridine phosphate (Firdapse®) is effective and safe in a phase 3 clinical trial in LEMS
SJ Oh, N Shcherbakova, A Kostera‐Pruszczyk, M Alsharabati, ...
Muscle & nerve 53 (5), 717-725, 2016
Antititin antibody in early‐and late‐onset myasthenia gravis
P Szczudlik, B Szyluk, M Lipowska, B Ryniewicz, J Kubiszewska, ...
Acta Neurologica Scandinavica 130 (4), 229-233, 2014
European cross-sectional survey of current care practices for Duchenne muscular dystrophy reveals regional and age-dependent differences
J Vry, K Gramsch, S Rodger, R Thompson, BF Steffensen, J Rahbek, ...
Journal of neuromuscular diseases 3 (4), 517-527, 2016
Genome-wide association study of late-onset myasthenia gravis: confirmation of TNFRSF11A and identification of ZBTB10 and three distinct HLA associations
MF Seldin, OK Alkhairy, AT Lee, JA Lamb, J Sussman, R Pirskanen-Matell, ...
Molecular Medicine 21 (1), 769-781, 2015
Titin antibodies in “seronegative” myasthenia gravis—a new role for an old antigen
C Stergiou, K Lazaridis, V Zouvelou, J Tzartos, R Mantegazza, C Antozzi, ...
Journal of neuroimmunology 292, 108-115, 2016
Incidence of spinal muscular atrophy in Poland–more frequent than predicted?
M Jedrzejowska, M Milewski, J Zimowski, P Zagozdzon, ...
Neuroepidemiology 34 (3), 152-157, 2010
MuSK‐positive myasthenia gravis is rare in the Polish population
A Kostera‐Pruszczyk, A Kamińska, M Dutkiewicz, B Emeryk‐Szajewska, ...
European journal of neurology 15 (7), 720-724, 2008
Charcot–Marie–Tooth type 4F disease caused by S399fsx410 mutation in the PRX gene
D Kabzińska, H Drac, DL Sherman, A Kostera-Pruszczyk, PJ Brophy, ...
Neurology 66 (5), 745-747, 2006
The system can't perform the operation now. Try again later.
Articles 1–20